GLP-1 medications UK — 7 proven options for weight loss in 2026.

The landscape of GLP-1 medications UK patients can access has changed dramatically over the past three years. What began with a single approved option has expanded into a growing menu of weekly injections — each with different mechanisms, different results, and different appropriate patient profiles. If you are trying to decide which weight loss injection is right for you in 2026, this guide gives you the complete picture.

All clinical data in this guide is drawn from published Phase 2 and Phase 3 trial results. The NHS obesity treatment guidelines and the NICE technology appraisal on Semaglutide for weight management provide the regulatory framework within which these medications are evaluated in the UK. At Mymetabolism, we supply all major GLP-1 medications UK customers ask for — verified, HPLC-tested, and shipped free across the UK.

What are GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1 — a hormone naturally produced in the gut after eating that signals fullness to the brain and stimulates insulin release. GLP-1 medications UK patients use are synthetic versions of this hormone designed to activate these pathways continuously via a weekly injection. By mimicking and amplifying GLP-1’s natural effects, these medications reduce appetite, slow gastric emptying, improve insulin sensitivity, and produce sustained weight loss.

The most significant recent development in GLP-1 medications UK availability is the emergence of dual and triple receptor agonists — medications that activate not just GLP-1 but also GIP and glucagon receptors. Each additional pathway produces meaningfully greater weight loss results. The progression from single (Ozempic) to dual (Mounjaro) to triple receptor activation (Retatrutide) represents the most rapid advancement in obesity pharmacotherapy in history.

All GLP-1 medications UK 2026 — comparison table

Here is a complete at-a-glance comparison of the major weight loss injections available in the UK from Mymetabolism in 2026:

Mounjaro (Tirzepatide) — the most popular GLP-1 UK choice

Mounjaro is currently the most popular choice among GLP-1 medications UK customers at Mymetabolism. It is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly — the first medication of its kind to activate two hormonal pathways simultaneously. The SURMOUNT-1 Phase 3 trial showed an average weight loss of 22.5% at the 15mg dose over 72 weeks — the highest results of any approved weight loss medication before Retatrutide emerged.

Mounjaro starts at 2.5mg once weekly and escalates every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to the 15mg maintenance dose over 20 weeks. It is suitable for adults with a BMI of 30 or above, or a BMI of 27 or above with a weight-related health condition. Most customers who choose Mounjaro from our GLP-1 medications UK range report noticeable appetite suppression within the first two weeks, with meaningful weight loss typically beginning at the 7.5mg dose.

Best for: People wanting the best-established dual-agonist results with a strong clinical track record. The go-to choice if Ozempic results have plateaued. Buy Mounjaro from Mymetabolism →

Ozempic (Semaglutide) — established single-receptor GLP-1

Ozempic was one of the first widely available GLP-1 medications UK patients adopted for weight loss. It contains Semaglutide — a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves blood sugar regulation. The STEP-2 trial showed approximately 9.6% weight loss at the 1mg dose, while off-label use at 2mg produces results closer to 12–14%. Ozempic also has strong cardiovascular outcome data — the SELECT trial confirmed a 20% reduction in major cardiovascular events, making it particularly valuable for patients with existing heart disease.

Ozempic starts at 0.25mg once weekly and escalates through 0.5mg, 1mg, to 2mg as the maximum dose. Its side effect profile is well-understood after years of real-world use, and it remains one of the most studied medications in this class.

Best for: Patients with type 2 diabetes or cardiovascular disease who want weight loss alongside metabolic management. Also suitable for those new to GLP-1 medications who prefer an established, well-understood option. Buy Ozempic from Mymetabolism →

Wegovy (Semaglutide 2.4mg) — the weight loss-specific Semaglutide

Wegovy contains the same active ingredient as Ozempic — Semaglutide — but at a higher maximum dose of 2.4mg weekly, specifically licensed for weight management rather than diabetes. The STEP-1 trial showed an average weight loss of 14.9% over 68 weeks at the 2.4mg dose, making it one of the most effective single-receptor GLP-1 medications UK patients can access. The higher dose also means more pronounced appetite suppression than standard Ozempic, with results that sit meaningfully closer to Mounjaro than the standard Ozempic dose achieves.

Wegovy follows a five-step escalation from 0.25mg to 2.4mg over 20 weeks. The 2026 approval of an oral Wegovy pill at 25mg in the US — expected in the UK later in 2026 — will make Semaglutide accessible to patients who cannot tolerate injections.

Best for: Patients who respond well to Semaglutide and want the maximum dose for weight management, or those who have used Ozempic and want to step up to the higher weight-loss-specific dose. Buy Wegovy from Mymetabolism →

Retatrutide — the most powerful weight loss injection available

Retatrutide is the most powerful option in our GLP-1 medications UK range — a first-in-class triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. The TRIUMPH-1 Phase 3 trial published in May 2026 showed average weight loss of 28.3% at the 12mg dose over 80 weeks. Forty-five percent of patients lost 30% or more — a threshold previously associated only with bariatric surgery.

The additional glucagon receptor activation is the key differentiator — it increases energy expenditure by stimulating direct fat burning in the liver, a mechanism absent from all other weight loss medications. Retatrutide follows a 12-week escalation from 2mg to the 9mg or 12mg maintenance dose. It is available from Mymetabolism as both VLS Retatrutide and Synedica Retatrutide.

Best for: Patients who want the most powerful weight loss results available, those who have plateaued on Mounjaro or CagriReta, and those with a high starting BMI seeking maximum clinical impact. Buy Retatrutide from Mymetabolism →

CagriReta — the dual amylin and GLP-1 combination

CagriReta combines two separate medications — Cagrilintide (an amylin analogue) and Semaglutide — in a single weekly injection. Unlike other entries in the GLP-1 medications UK range, CagriReta’s second mechanism works via amylin receptor activation rather than GIP. The REDEFINE 1 trial showed average weight loss of 20.4% over 68 weeks, with 60% of participants achieving at least 20% body weight loss and 23% losing 30% or more.

CagriReta is a compelling option for patients who want results beyond standard Semaglutide but through a different dual mechanism than Mounjaro. It is particularly notable for its metabolic benefits — 88% of participants with prediabetes returned to normal blood glucose levels by week 68.

Best for: Patients seeking dual-mechanism results via a non-tirzepatide pathway, particularly those with prediabetes or metabolic syndrome alongside obesity. Buy CagriReta from Mymetabolism →

How to choose the right GLP-1 medication UK

Choosing between GLP-1 medications UK patients can access in 2026 comes down to four key factors: your weight loss goal, your health history, your tolerance for dose escalation, and your previous experience with this class of medication.

• If you want maximum weight loss results: Retatrutide at 12mg is the most powerful option currently available. Clinical data does not leave ambiguity — 28.3% average weight loss versus 22% for Mounjaro and 15% for Wegovy
• If you want proven dual-mechanism results with established safety data: Mounjaro (Tirzepatide) is the most popular choice and the most extensively studied dual agonist. Excellent results with a growing real-world safety profile
• If you have cardiovascular disease or type 2 diabetes: Ozempic has the strongest cardiovascular outcome data of any medication in this class. The SELECT trial cardiovascular benefit is specific to Semaglutide and has not yet been replicated for newer agents
• If you have plateaued on Mounjaro: Consider escalating to Retatrutide or CagriReta — both work through mechanisms that are additive to or different from Tirzepatide’s pathway
• If you are new to GLP-1 medications: Start with Mounjaro — it offers the best balance of proven results, established tolerability, and clinical evidence for a first-time patient in 2026